Overview
Jay Salpekar, M.D. is Director of the Neuropsychiatry in Epilepsy Program at Kennedy Krieger Institute, and on the full time faculty of Johns Hopkins University Medical School. He received B.A. and M.D. degrees from Washington University in St. Louis and continued at Barnes Hospital for internship and residency training in general psychiatry. He then completed a child and adolescent psychiatry fellowship at the Yale University Child Study Center. Dr. Salpekar is widely published in the field of pediatric neuropsychiatry. He is a reviewer for scientific journals, grant review panels, and serves on the editorial board for Epilepsy and Behavior. He is active in the American Epilepsy Society, Epilepsy Foundation, and was recently honored with Fellow status in the American Neuropsychiatric Association.
Dr. Salpekar is highly rated in 11 conditions, according to our data. His top areas of expertise are Epilepsy, Seizures, Attention Deficit Hyperactivity Disorder (ADHD), and Spasmus Nutans.
His clinical research consists of co-authoring 59 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE SNP
- OTHER MEDICARE PART D
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MEDICAID
- STATE MEDICAID
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE ASSISTANCE PROGRAM
- MEDICARE MAPD
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
Floor 2, Baltimore, MD 21205
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Johns Hopkins Outpatient Center
Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is highly rated in 27 conditions, according to our data. Her top areas of expertise are Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy.
Children's Hospital
William Gaillard is a Psychiatrist and a Pediatrics provider in Washington, Washington, D.c.. Dr. Gaillard is highly rated in 29 conditions, according to our data. His top areas of expertise are Epilepsy, Seizures, Status Epilepticus, Liver Embolization, and Deep Brain Stimulation. Dr. Gaillard is currently accepting new patients.
Johns Hopkins Outpatient Center
Dr. Alexander Pantelyat cares for patients with movement disorders such as Parkinson's disease and related syndromes, essential tremor, dystonia, chorea and normal pressure hydrocephalus. He also provides botulinum toxin injections for movement disorders and is involved in deep brain stimulation programming and intraoperative neurophysiological monitoring.His research explores atypical parkinsonian disorders, such as dementia with Lewy bodies, progressive supranuclear palsy, corticobasal syndrome/degeneration and multiple system atrophy; cognitive aspects of movement disorders; and music-based rehabilitation of neurodegenerative diseases.Dr. Pantelyat earned his medical degree from Temple University School of Medicine in Philadelphia, where he was elected a member of the Alpha Omega Alpha Honor Medical Society and received the Matthew T. Moore Prize in Neurology. He completed his residency training in Neurology at the University of Pennsylvania in Philadelphia, and a fellowship in movement disorders at the University of Pennsylvania/Philadelphia VA Medical Center. As part of his fellowship, Dr. Pantelyat also completed the Clinical Research Certificate Program at the Center for Clinical Epidemiology and Biostatistics. He is a 2013 American Academy of Neurology Palatucci Advocacy Leader and grant recipient. Dr. Pantelyat is highly rated in 39 conditions, according to our data. His top areas of expertise are Progressive Supranuclear Palsy, Progressive Supranuclear Palsy Atypical, Supranuclear Ophthalmoplegia, and Corticobasal Degeneration.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- EpilepsyDr. Salpekar isDistinguished. Learn about Epilepsy.
- Advanced
- Attention Deficit Hyperactivity Disorder (ADHD)
- Autism Spectrum DisorderDr. Salpekar isAdvanced. Learn about Autism Spectrum Disorder.
- Autosomal Dominant Partial Epilepsy with Auditory Features
- Dravet SyndromeDr. Salpekar isAdvanced. Learn about Dravet Syndrome.
- Lafora DiseaseDr. Salpekar isAdvanced. Learn about Lafora Disease.
- Progressive Myoclonic EpilepsyDr. Salpekar isAdvanced. Learn about Progressive Myoclonic Epilepsy.
- Experienced
- Accessory Deep Peroneal NerveDr. Salpekar isExperienced. Learn about Accessory Deep Peroneal Nerve.
- Bipolar Disorder (BPD)Dr. Salpekar isExperienced. Learn about Bipolar Disorder (BPD).
- EpendymomaDr. Salpekar isExperienced. Learn about Ependymoma.
- Epilepsy Juvenile AbsenceDr. Salpekar isExperienced. Learn about Epilepsy Juvenile Absence.
- Generalized Anxiety Disorder (GAD)Dr. Salpekar isExperienced. Learn about Generalized Anxiety Disorder (GAD).
- Generalized Tonic-Clonic SeizureDr. Salpekar isExperienced. Learn about Generalized Tonic-Clonic Seizure.